J. Michael Pearson (born 1959) is a Canadian American pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International, until ousted in April 2016, in the aftermath of a report published by Citron Research. On April 27, 2016 Pearson, Bill Ackman and Howard Schiller appeared before the United States Senate Special Committee on Aging to answer concerns about the repercussions for patients and the health care system faced with Valeant's business model.

Property Value
dbo:abstract
  • J. Michael Pearson (born 1959) is a Canadian American pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International, until ousted in April 2016, in the aftermath of a report published by Citron Research. On April 27, 2016 Pearson, Bill Ackman and Howard Schiller appeared before the United States Senate Special Committee on Aging to answer concerns about the repercussions for patients and the health care system faced with Valeant's business model. Pearson is currently suing Valeant Pharmaceuticals for $32 million, as compensation for his alleged wrongful termination as CEO and chairman. In December 2017 a New Jersey judge ruled that Pearson should pursue his claim by arbitration rather than through the courts. (en)
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2020-01-03 13:32:51Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 31362220 (xsd:integer)
dbo:wikiPageLength
  • 27046 (xsd:integer)
dbo:wikiPageModified
  • 2020-01-03 13:32:45Z (xsd:date)
dbo:wikiPageOutDegree
  • 62 (xsd:integer)
dbo:wikiPageRevisionID
  • 933871683 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • J. Michael Pearson (born 1959) is a Canadian American pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International, until ousted in April 2016, in the aftermath of a report published by Citron Research. On April 27, 2016 Pearson, Bill Ackman and Howard Schiller appeared before the United States Senate Special Committee on Aging to answer concerns about the repercussions for patients and the health care system faced with Valeant's business model. (en)
rdfs:label
  • J. Michael Pearson (en)
owl:sameAs
foaf:gender
  • male (en)
foaf:isPrimaryTopicOf
is dbo:wikiPageDisambiguates of
is foaf:primaryTopic of